# Transplant ureteric stent removal: early versus standard removal

Submission date	Recruitment status	[X] Prospectively registered	
<b>Registration date</b> 22/04/2010	<b>Overall study status</b> Completed	[X] Protocol [ ] Statistical analysis plan	
		[X] Results	
Last Edited 13/02/2017	<b>Condition category</b> Urological and Genital Diseases	Individual participant data	

# Plain English summary of protocol

Not provided at time of registration

# **Contact information**

**Type(s)** Scientific

**Contact name** Mr Jonathon Olsburgh

# Contact details

Guy's Hospital 6th Floor Renal Offices St Thomas Street London United Kingdom SE1 9RT

# Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

Secondary identifying numbers N/A

# Study information

# Scientific Title

Transplant ureteric stent removal: early versus standard removal - a randomised controlled trial

### Acronym

TrUST

## **Study objectives**

During kidney transplantation a plastic tube (stent) is placed in the transplant ureter, between the renal pelvis and the bladder. Meta-analyses of randomised controlled trials on the use of transplant ureteric stents (TUS) have shown that routine use of a TUS reduces major posttransplant urological complications, particularly urinary leaks and ureteric stenosis. However stent complications occur in around 20% of patients, both adults and children. Studies suggest that TUS complications; which include urine infection, stent migration and pain; are related to the time stents remain in-situ.

The optimum timing for stent removal is currently not known, however recent studies suggest that stents should be removed at 2 to 4 weeks post-transplantation. In our centre we have reduced the time that our ureteric stents remain in-situ from 12 to 6 weeks post-transplant on the basis of internal audit of transplant stent complications. Nevertheless, we continue to observe a 15 - 20% post transplant ureteric stent complication rate. We currently remove the stent using cystoscopy and to minimise associated risks do not advocate routinely performing the procedure before 6 weeks post-transplantation.

A new technique of suturing the ureteric stent to the urethral catheter was described in 1998. This technique allows early removal of both the stent and urethral catheter together without the need for cystoscopy. We hypothesise that this new technique would enable us to remove the stent at an earlier date and reduce the complication rate associated to ureteric stents in-situ for prolonged periods.

# Ethics approval required

Old ethics approval format

**Ethics approval(s)** London Research Ethics Committee (REC), 27/01/2010, ref: 10/H0718/5

**Study design** Randomised controlled trial

**Primary study design** Interventional

**Secondary study design** Randomised controlled trial

**Study setting(s)** Hospital

**Study type(s)** Treatment

Participant information sheet

Not available in web format, please use the contact details to request a patient information sheet

# Health condition(s) or problem(s) studied

Urological issues in renal transplants

## Interventions

There are two potential study arms to which patients are allocated: Group 1: Standard technique for Transplant Ureteric Stent removal (sTUSr), or Group 2: New technique with early Transplant Ureteric Stent removal (eTUSr)

A TUS is placed at the time of surgery along with a urinary catheter in all patients. Patients in the standard arm (Group 1) will have the urinary catheter removed on the ward on the 5th post-operative day. They will then undergo a cystoscopy, under either local or general anaesthetic, at week 6 to remove the TUS. Patients in the trial arm (Group 2) will have the TUS attached to the urinary catheter at the time of surgery. These patients will have the urinary catheter removed on the ward on the 5th post-operative day in the standard way. As the TUS is attached to the catheter it will be removed at the same time as removal of the catheter. This group therefore do not require cystoscopy.

The study will be performed prospectively. Patients that require kidney transplantation will be recruited and allocated to a study arm. Participants of the study will be followed up in the same way as non-participants. A diary card will be completed by those in group 1 on the day of their cystoscopy. Stent related symptom assessment and quality of life questionnaires will be completed by all participants at week 1 and week 6. Data will be collected on all participants regarding ureteric complications, stent related complications, health economics and patient quality of life assessments for 3 months post-transplantation. Complications of ureteric stenosis will monitored for up to 6 months post-transplantation.

## Intervention Type

Procedure/Surgery

# Primary outcome measure

Stent-related complications, specifically urinary infection, pain and migration. Information collected at each OP visit for 3 months.

# Secondary outcome measures

1. Rate of transplant ureteric leak or stenosis: information collected at each OP visit for up to 6 months

2. Patient acceptability, measured with quality of life questionnaires at week 1 and week 6 3. Economic costs (hospital and patient): Patient diary card on day of stent removal, hospital costs can be evaluated at 6 months

# Overall study start date

01/04/2010

Completion date 15/12/2015

# Eligibility

## Key inclusion criteria

1. Children aged 2 - 16 years, either sex

2. Adults aged 17 - 75 years, either sex

3. Needing kidney transplant

## Participant type(s)

Patient

### Age group

Mixed

# Sex

Both

# Target number of participants

88 patients per group (176 patients in total)

## Key exclusion criteria

1. Urinary Tract exclusion:

- 1.1. Urinary diversion e.g. ileal conduit, cutaneous ureterostomy, mitrofanoff
- 1.2. Duplex transplant ureter
- 1.3. Pelviureteric junction obstruction
- 1.4. Surgical concern regarding the vascularity of the transplant ureter
- 1.5. Donor kidney stone and use of bench (ex-vivo) ureteroscopy
- 1.6. Early use of mammalian target of rapamycin (mTOR) inhibitors (early use is very uncommon as the drug has well documented concerns regarding worse tissue healing)

2. Risk of bleeding:

- 2.1. Kidney capsule removed at retrieval
- 2.2. Need for post-operative systemic heparinisation

2.3. Greater than 3 cycles of pre-operative plasma exchange (DFFP) as part of transplant desensitisation program

3. Simultaneous kidney and pancreas transplant (SPK)

## Date of first enrolment

27/05/2010

Date of final enrolment 22/11/2013

# Locations

**Countries of recruitment** England

United Kingdom

**Study participating centre Guy's Hospital** London United Kingdom SE1 9RT

# Sponsor information

#### Organisation

Guy's and St Thomas' NHS Foundation Trust (UK)

### **Sponsor details**

c/o Jennifer Boston Guy's Hospital 2nd Floor Conybeare House St Thomas Street London England United Kingdom SE1 9RT +44 (0)20 7188 5736 Jennifer.boston@gstt.nhs.uk

# Sponsor type

Hospital/treatment centre

Website http://www.guysandstthomas.nhs.uk/

#### ROR https://ror.org/00j161312

# Funder(s)

**Funder type** Government

#### **Funder Name**

National Institute for Health Research (NIHR) (UK) - Research for Patient Benefit (RfPB) Programme (ref: PB-PG-0909-20047) - grant pending, outcome due July 2010

# **Results and Publications**

#### **Publication and dissemination plan** The results are expected to be published in early 2016

# Intention to publish date

# Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol file	version v2	14/12/2010	28/09/2016	Νο	No
Results article	results	01/08/2017		Yes	No